“The ADAPT AF-DES trial confirmed that no antiplatelet therapy should be used in chronic coronary syndrome patients receiving oral anticoagulation. First, it carries no benefit in terms of antithrombotic events, and it harms a lot in terms of bleeding and death. In 2025, [the answer] is just simple: no way. The question that remains is when should we stop all antiplatelet agents after the acute event or last PCI.”
A Wed, study studied this question.